标题
Update on incretin hormones
作者
关键词
-
出版物
Annals of the New York Academy of Sciences
Volume 1243, Issue 1, Pages E55-E74
出版商
Wiley
发表日期
2012-04-20
DOI
10.1111/j.1749-6632.2012.06491.x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- GLP-1 Receptor Stimulation Reduces Amyloid-β Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease
- (2017) Yazhou Li et al. JOURNAL OF ALZHEIMERS DISEASE
- Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes
- (2013) John B. Buse et al. ANNALS OF INTERNAL MEDICINE
- The role of the gut sweet taste receptor in regulating GLP-1, PYY, and CCK release in humans
- (2011) A. C. Gerspach et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
- (2011) Robert Ratner et al. Cardiovascular Diabetology
- Snapin Mediates Incretin Action and Augments Glucose-Dependent Insulin Secretion
- (2011) Woo-Jin Song et al. Cell Metabolism
- Intracellular Signals Mediating the Food Intake-Suppressive Effects of Hindbrain Glucagon-like Peptide-1 Receptor Activation
- (2011) Matthew R. Hayes et al. Cell Metabolism
- Neuroprotective properties of GLP-1: theoretical and practical applications
- (2011) Jens Juul Holst et al. CURRENT MEDICAL RESEARCH AND OPINION
- Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
- (2011) M. A. Nauck et al. DIABETES
- Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes: A randomized 26-week study on glycemic control and hypoglycemia
- (2011) B. Gallwitz et al. DIABETES CARE
- DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors
- (2011) D. Dicker DIABETES CARE
- Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes
- (2011) R. R. Henry et al. DIABETES OBESITY & METABOLISM
- A cohort study of acute pancreatitis in relation to exenatide use
- (2011) D. D. Dore et al. DIABETES OBESITY & METABOLISM
- An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future
- (2011) S. Madsbad et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs
- (2011) K. R. Hjøllund et al. DIABETOLOGIA
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
- (2011) Jacob Lønborg et al. EUROPEAN HEART JOURNAL
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
- (2011) Michael Elashoff et al. GASTROENTEROLOGY
- GLP-1–Based Therapies: The Dilemma of Uncertainty
- (2011) Joachim Spranger et al. GASTROENTEROLOGY
- Incretin-based therapies - review of the physiology, pharmacology and emerging clinical experience
- (2011) J. H. Martin et al. INTERNAL MEDICINE JOURNAL
- Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as “Isoglycemic” Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes
- (2011) Irfan Vardarli et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Changes in Glucose Homeostasis after Roux-en-Y Gastric Bypass Surgery for Obesity at Day Three, Two Months, and One Year after Surgery: Role of Gut Peptides
- (2011) Y. Falkén et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
- (2011) Thomas Blevins et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials
- (2011) John B. Buse et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis
- (2011) Safina Ali et al. JOURNAL OF CLINICAL INVESTIGATION
- Sub-chronic administration of stable GIP analog in mice decreases serum LPL activity and body weight
- (2011) Ewa Szalowska et al. PEPTIDES
- Incretin-Based Therapies: Review of Current Clinical Trial Data
- (2010) Anne Peters AMERICAN JOURNAL OF MEDICINE
- Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications
- (2010) Michael A. Nauck AMERICAN JOURNAL OF MEDICINE
- Glucagon-Like Peptide-1 Analog and Insulin Combination Therapy in the Management of Adults with Type 2 Diabetes Mellitus
- (2010) Maria Tzefos et al. ANNALS OF PHARMACOTHERAPY
- Feeding and bone
- (2010) Jennifer S. Walsh et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Role of the glucose-dependent insulinotropic polypeptide and its receptor in the central nervous system: therapeutic potential in neurological diseases
- (2010) Cláudia P. Figueiredo et al. BEHAVIOURAL PHARMACOLOGY
- Pre-treatment with a DPP-4 Inhibitor is Infarct Sparing in Hearts from Obese, Pre-diabetic Rats
- (2010) Barbara Huisamen et al. CARDIOVASCULAR DRUGS AND THERAPY
- Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
- (2010) M. Arakawa et al. DIABETES
- The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1
- (2010) G. P. Fadini et al. DIABETES CARE
- Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin: A proof-of-concept study
- (2010) S. Arnolds et al. DIABETES CARE
- Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
- (2010) B. Ahren et al. DIABETES CARE
- Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents
- (2010) J. B. Buse et al. DIABETES CARE
- Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database
- (2010) J. H. Best et al. DIABETES CARE
- Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
- (2010) A. J. Scheen DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1(9-36)amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice
- (2010) E. Tomas et al. DIABETES OBESITY & METABOLISM
- Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes
- (2010) M. C. Bunck et al. DIABETES OBESITY & METABOLISM
- Exenatide Versus Glibenclamide in Patients with Diabetes
- (2010) G. Derosa et al. Diabetes Technology & Therapeutics
- Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
- (2010) André J. Scheen et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
- (2010) M. A. Nauck et al. DIABETOLOGIA
- GLP-1(7-36)-amide and Exendin-4 Stimulate the HPA Axis in Rodents and Humans
- (2010) Manuel Gil-Lozano et al. ENDOCRINOLOGY
- Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor
- (2010) Kiwon Ban et al. ENDOCRINOLOGY
- Differential Effects of PPAR-γ ActivationversusChemical or Genetic Reduction of DPP-4 Activity on Bone Quality in Mice
- (2010) Kimberly A. Kyle et al. ENDOCRINOLOGY
- Role of the SDF-1-CXCR4 axis in stem cell-based therapies for ischemic cardiomyopathy
- (2010) Marc-Michael Zaruba et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
- (2010) S. S. Engel et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor
- (2010) Bernardo Nuche-Berenguer et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
- (2010) Richard E Pratley et al. LANCET
- Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors
- (2010) Jaime A. Davidson MAYO CLINIC PROCEEDINGS
- Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge
- (2010) Richa Saxena et al. NATURE GENETICS
- Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice
- (2010) Simon Gengler et al. NEUROBIOLOGY OF AGING
- Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy
- (2010) Mary Parks et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exenatide therapy in insulin-treated type 2 diabetes and obesity
- (2010) U. A. Nayak et al. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
- Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
- (2010) Debora Williams-Herman et al. BMC Endocrine Disorders
- Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes
- (2009) T. Okerson et al. AMERICAN JOURNAL OF HYPERTENSION
- Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow
- (2009) C. Sanz et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Impact of Sitagliptin on Markers of β-cell Function: A Meta-Analysis
- (2009) Daniel M. Riche et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide
- (2009) Lisbeth V. Jacobsen et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of GLP-1 Treatment on Bone Turnover in Normal, Type 2 Diabetic, and Insulin-Resistant States
- (2009) Bernardo Nuche-Berenguer et al. CALCIFIED TISSUE INTERNATIONAL
- Synergy between CD26/DPP-IV Inhibition and G-CSF Improves Cardiac Function after Acute Myocardial Infarction
- (2009) Marc-Michael Zaruba et al. Cell Stem Cell
- Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors
- (2009) J. A. DAVIDSON CLEVELAND CLINIC JOURNAL OF MEDICINE
- Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
- (2009) David D. Dore et al. CURRENT MEDICAL RESEARCH AND OPINION
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
- (2009) B. Zinman et al. DIABETES CARE
- The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
- (2009) R. A. DeFronzo et al. DIABETES CARE
- Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes: A retrospective cohort study
- (2009) R. A. Noel et al. DIABETES CARE
- Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
- (2009) E. Ferrannini et al. DIABETES OBESITY & METABOLISM
- Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
- (2009) E. Bosi et al. DIABETES OBESITY & METABOLISM
- Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
- (2009) M. Marre et al. DIABETIC MEDICINE
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
- (2009) D. Russell-Jones et al. DIABETOLOGIA
- Minireview: Finding the Sweet Spot: PeripheralVersusCentral Glucagon-Like Peptide 1 Action in Feeding and Glucose Homeostasis
- (2009) Diana L. Williams ENDOCRINOLOGY
- Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice
- (2009) Michele D’Amico et al. EXPERIMENTAL GERONTOLOGY
- Gut peptides in the control of food intake
- (2009) T H Moran INTERNATIONAL JOURNAL OF OBESITY
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
- (2009) Y. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Stromal Cell–Derived Factor-1α Is Cardioprotective After Myocardial Infarction
- (2008) Ankur Saxena et al. CIRCULATION
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
- (2008) Kiwon Ban et al. CIRCULATION
- Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat
- (2008) Indu Poornima et al. Circulation-Heart Failure
- Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
- (2008) T MORETTO et al. CLINICAL THERAPEUTICS
- Exendin-4 Improves Glycemic Control, Ameliorates Brain and Pancreatic Pathologies, and Extends Survival in a Mouse Model of Huntington's Disease
- (2008) B. Martin et al. DIABETES
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2008) D. M. Nathan et al. DIABETES CARE
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
- (2008) M. Nauck et al. DIABETES CARE
- Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes*
- (2008) R. Scott et al. DIABETES OBESITY & METABOLISM
- Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes
- (2008) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension
- (2008) Goutam C. Mistry et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease
- (2008) Alexander Harkavyi et al. Journal of Neuroinflammation
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
- Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
- (2008) Alan Garber et al. LANCET
- Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?
- (2008) Juris J Meier et al. Nature clinical practice. Endocrinology & metabolism
- EFFECTS OF DIPEPTIDYL PEPTIDASE IV INHIBITION ON ARTERIAL BLOOD PRESSURE
- (2007) Edwin K Jackson et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- The Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption
- (2007) Chizumi Yamada et al. ENDOCRINOLOGY
- Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease
- (2007) Göran Bertilsson et al. JOURNAL OF NEUROSCIENCE RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now